ClinicalTrials.gg
RecruitingNCT07377721Updated Apr 15, 2026

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

A Phase 1 interventional study of HRS-2129 Tablets and HRS-2129 Placebo in Diabetic Peripheral Neuropathic Pain, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.

Planned enrollment
15th of 30
168 · median 158
Started
2026
with 3 others
Phase 1
2 of 40
2 open now
Primary completion
2026-09
later than 9 of 15 live
Registered
36th of 40
by date

Among the 40 studies in Neuralgia with a site in China, this one is the 15th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 9 of the 15 other live ones, and was the 36th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Males or females aged ≥18years of age inclusive.
  3. Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral neuropathy (DPN) pain ≥ 3 months.
  4. ≤ 9.0% at screening and on a stable antidiabetic medication regimen for at least 30 days prior to screening as far as possible.
  5. At Screening, pain scale (Visual Analog Scale, VAS) of ≥ 40 mm and \< 90 mm.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of severe allergies.
  2. Peripheral neuropathy or pain unrelated to diabetic peripheral neuropathy (DPN) that may confuse the assessment of diabetic peripheral neuropathic pain (DPNP).
  3. Subjects with abnormal liver and renal function.
  4. Interval (QTc): > 450 ms (male), > 470 ms (female).
  5. Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or gabapentin at doses ≥ 1200 mg/d for treatment of diabetic peripheral neuropathic pain (DPNP).
  6. History of suicidal behavior or attempted suicide.
  7. Participated in another clinical study within 3 months prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    HRS-2129 High Dose Group

    Drug: HRS-2129 Tablets · Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo

  • Experimental
    HRS-2129 Low Dose Group

    Drug: HRS-2129 Tablets · Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo

  • Active comparator
    Pregabalin Group

    Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules

  • Placebo comparator
    Blank Preparation Placebo Group

    Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo

Interventions

  • HRS-2129 tablets.

  • DrugHRS-2129 Placebo

    HRS-2129 placebo.

  • Pregabalin capsules.

  • DrugPregabalin Capsules Placebo

    Pregabalin capsules placebo.

06

What researchers measure

Primary outcomes

  1. Compare the change from baseline in Average Daily Pain Score (ADPS) between HRS-2129 and placebo at Week 4.

    The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.

    Time frame: Baseline and Week 4.

Secondary outcomes

  1. Compare the response rate between HRS-2129 and placebo at Week 4 (Proportion of subjects whose ADPS decreased by ≥ 30% and ≥ 50% from baseline).

    Ratio of participants responding to treatment, as measured by Average Daily Pain Score (ADPS) reduction from baseline. The ADPS is used to determine categorical response rates.

    Time frame: Baseline and Week 4.

  2. Compare the change from baseline in ADPS between HRS-2129 and placebo at Week 1 to 4.

    The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.

    Time frame: From Week 1 to Week 4.

  3. Compare the change from baseline in Visual Analog Scale (VAS) between HRS-2129 and placebo at Week 4.

    VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.

    Time frame: Baseline and Week 4.

  4. Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) between HRS-2129 and placebo at Week 4.

    Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - 11 descriptors of pain intensity, and 4 descriptors of emotions, on a scale of 0 (none) to 3 (severe); Part 2 - a Visual Analog Scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).

    Time frame: Baseline and Week 4.

  5. Compare the Patient Global Impression of Change (PGIC) between HRS-2129 and placebo at Week 4.

    Patient Global Impression of Change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse.

    Time frame: At Week 4.

  6. Compare the change from baseline in Average Daily Sleep Interference score (ADSIS) between HRS-2129 and placebo at Week 4.

    The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores.

    Time frame: Baseline and Week 4.

  7. Number and severity of serious adverse events (SAEs).

    To evaluate the safety of HRS-2129 during the trial.

    Time frame: From Week 1 to Week 6.

  8. Number and severity of adverse events (AEs).

    To evaluate the safety of HRS-2129 during the trial.

    Time frame: From Week 1 to Week 6.

  9. Population Pharmacokinetics (PopPK) characteristics of HRS-2129 in Chinese patients with diabetic peripheral neuropathic pain - Serum concentration of HRS-2129.

    Population Pharmacokinetics (PopPK) will be determined by measuring serum concentration of HRS-2129.

    Time frame: From Day 0 to Day 30.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 30, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Nov 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377721
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Mar 24, 2026
Primary completion
Sep 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 15, 2026

Study contacts

Lei Tang
Contact
lei.tang.lt31@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2129

Start the discussion